FDA OKs pill to fight gum disease

Article Abstract:

CollaGenex Pharmaceutical will now be able to market Periostat, the drug to treat gum disease. The Food and Drug Administration approved the drug for use in patients after the "scaling and planing" process to remove bacteria from below the gum line. According to CollaGenex President and CEO Brian Gallagher, Periostat will help patients in controlling their advanced gum diseases by suppressing an enzyme that is responsible for the breakdown of the gums. Although Periostat is need expected to prevent gum disease, the American Dental Association is pleased with approval of the new drug.

Comment:

Will now be able to market Periostat, the drug to treat gum disease, because FDA has approved the drug on 10/1/98

Research & Development, Scientific Research and Development Services, Research institutes, CollaGenex Pharmaceuticals Inc., Article

---

Airlines could be sued for blood-clot threat

Article Abstract:

Airlines are facing legal challenges due to the health risk known as the economy-class syndrome. Slater and Gordon, a law firm in Sydney, Australia, is thinking of suing 20 airlines around the world and has signed 800 people, including the families of 36 people who have from deadly conditions resulting from the syndrome. The syndrome is a medical condition known as deep-vein thrombosis. The blood clots that lodge in a vital organ can result in a medical emergency such as a pulmonary embolism.

Legal issues & crime, Offices of Lawyers, Legal Services

---

Blood substitute may be the breakthrough

Article Abstract:

Alliance Pharmaceutical Corp's Oxygent, a milky white substance that has already been used in hundreds of clinical trials of patients who have undergone surgeries all over the worlds, is emerging as the prime candidate for a viable blood substitute. The substance, which is expected to be approved and commercially available in another year or so, will also have widespread uses in patients suffering from strokes or heart attacks.

Biological Product (except Diagnostic) Manufacturing, Blood Plasma Products, Blood plasma, Alliance Pharmaceutical Corp.

Similar abstracts:

• Abstracts: Daimler questions crash tests. Airlines extend review period for merger. Tensions rise as jet stays put
• Abstracts: Microsoft to refocus on users, Internet. Tires linked to 29 more deaths. Microsoft, Justice Department sparring
• Abstracts: Pixar movie profits may falter. Studios in animated war for viewer hearts, wallets. 'Survivor' raises CBS' hope of ratings rescue
• Abstracts: Murdoch doubles stake in Gemstar. MP3 ordered to pay $250M for copyright violation

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.